Lupin appoints Theresa Stevens as Chief Corporate Development Officer

Lupin has appointed Theresa Stevens as Chief Corporate Development Officer for its global operations. Theresa will assume full responsibility for global merger and acquisitions and specialty business strategy. Prior to joining Lupin, Theresa was with Aptalis pharma as the Chief Corporate Development Officer responsible for mergers & acquisitions (M&A), strategy and global business development. Before Aptalis, Theresa was in Novartis for more than 9 years and held positions of increasing responsibility including Head, Global BD&L for General Medicines, Executive Director and Head, Global BD&L for Respiratory and Dermatology Business Units and Head US Business Development & Licensing, Life cycle management and generic brand strategies.
 
Commenting on the appointment, Nilesh Gupta, Managing Director, Lupin Limited, said, “I am very pleased to welcome Theresa to the Lupin family. I am sure her rich experience in the areas of M&A and specialty strategy within the pharmaceutical and biotech industry sector will help Lupin’s growth plans.”